Hybrid implant made of a composite material
The present invention relates to a (poly)hybrid implant made of one or more composite materials, having a polymer matrix and a ceramic-inorganic and/or inorganic component, wherein the polymer matrix has at least one component, selected from the group PDLLA; PLGA, PCL, HDPE, PE, UHMWPE, PEAK, PEEK, PP, PUR, and the ceramic-inorganic component has at least one calcium-phosphate-based component, preferably selected from the group HAP, α-TCP, β-TCP and CaCO 3 . In addition, metallic components can also be introduced, preferably, but not exclusively containing elements such as Mg, Fe, Zn or Sr.
1. A hybrid implant made of a composite material comprising a polymer matrix and a ceramic-inorganic component, wherein
the polymer matrix has at least one component selected from the group of PDLLA, PLGA, PCL, HDPE, PE, UHMWPE, PEAK, PEEK, PP, and PUR;
the ceramic-inorganic component contains biodegradable CaCO 3 as a polymer degradation accelerator, wherein degradation of the hybrid implant uniformly releases calcium ions as an inductive factor on the entire surface of the hybrid implant, and wherein the CaCO 3 is present as substantially spherical particles.
2. The hybrid implant according to claim 1 , wherein the CaCO 3 contributes between 15%-65% percentage by weight to the total mass of the hybrid implant.
3. The hybrid implant according to claim 1 , wherein the spherical particles comprise at least one group of spherical particles having a diameter selected from 10 μm-15 μm, 20 μm-25 μm, 30 μm-45 μm, or 100 μm-200 μm.
4. The hybrid implant according to claim 3 , wherein the spherical particles on their surface show a defined topography.
5. The hybrid implant according to claim 3 , wherein the spherical particles on their surface show a hydrophilic surface modification.
6. The hybrid implant according to claim 3 , wherein the spherical particles on their surface show a lipophilic surface modification.
7. The hybrid implant according to claim 1 , wherein the hybrid implant is formed as a scaffold structure for tissue conduction having a diameter of 100 μm-800 μm.
8. The hybrid implant according to claim 1 , wherein the hybrid implant additionally contains tissue-inductive and/or tissue-conductive factors.
9. The hybrid implant according to claim 1 , prepared by a sinter-less 3D additive method at a temperature between room temperature and about 250° C.
10. The hybrid implant according to claim 1 , prepared by subtractive removal of a starting material.
11. The hybrid implant according to claim 1 , wherein the CaCO 3 contributes between 15%-25% percentage by weight to the total mass of the hybrid implant.
12. The hybrid implant according to claim 1 , wherein the CaCO 3 contributes between 25%-35% percentage by weight to the total mass of the hybrid implant.
13. The hybrid implant according to claim 1 , wherein the CaCO 3 contributes between 50%-65% percentage by weight to the total mass of the hybrid implant.
14. The hybrid implant according to claim 1 , wherein the hybrid implant is formed as a scaffold structure for tissue conduction having a diameter of 300 μm-450 μm.
15. The hybrid implant according to claim 1 , wherein the hybrid implant further comprises non-proteinogenic chemical messengers and/or ions, and/or other active agents.
16. The hybrid implant according to claim 1 , wherein the composite material further comprises at least one metallic component.
17. The hybrid implant according to claim 16 , wherein the at least one metallic component shows an irregular shaping or is configured to be substantially spherical, fibrous, twisted or helical.
18. The hybrid implant according to claim 16 , wherein the at least one metallic component is at least one selected from the group consisting of magnesium, iron, zinc, and strontium.